Medscape (7/20, Brooks, Subscription Publication) reports, “The global prevalence of young-onset dementia (YOD) is significantly higher than previously thought,” investigators concluded in a 74-study, 2.7 million-participant systematic review and meta-analysis showing that “currently, 3.9 million individuals are living with YOD” in which “symptoms of the memory-robbing disease start before age 65.” The findings were published online July 19 in JAMA Neurology.

Related Links:

— Medscape (requires login and subscription)

Psychiatric News (7/20) reports researchers have provided “a comprehensive overview of the neurological and psychiatric impact of the COVID-19 pandemic.” They did so by compiling “data from individual case reports, cohort studies, and meta-analyses on the neurological and psychiatric outcomes in patients with SARS-CoV-2 infection.” The study authors observed, “CNS infection combined with environmental stress caused by pandemic fear, social and financial restrictions, and ICU monitoring may result in the development of neuropsychiatric symptoms or syndromes, including depressive symptoms or episodes, manic or hypomanic symptoms or episodes, psychotic symptoms, obsessive-compulsive symptoms, and posttraumatic stress.” The findings were published online July 19 in the Journal of Neuropsychiatry and Clinical Neurosciences, a publication of the American Psychiatric Association.

Related Links:

— “COVID-19 Has Numerous Neuropsychiatric Consequences, Report Finds, Psychiatric News, July 20, 2021

Healio (7/20, Gramigna) reports, “Individuals with eating disorders had nearly nine times greater risk for lifetime OCD and eight times greater risk for current OCD vs. healthy controls,” researchers concluded in an “epidemiological meta-analysis” that “identified 846 articles,” then “calculated 35 lifetime and 42 current estimates.” The findings were published online ahead of print in the September issue of the Journal of Psychiatric Research.

Related Links:

— “People with eating disorders have nine times greater risk for lifetime OCD “Joe Gramigna, Healio, July 20, 2021

Psychiatric News (7/19) reports, “Patients with schizophrenia may be less likely to stop treatment if prescribed clozapine or the long-acting injectable (LAI) formulations of aripiprazole and paliperidone compared with oral olanzapine,” investigators concluded in a study that “made use of data from over 37,000 veterans.” The findings were published online July 14 in the American Journal of Psychiatry, a publication of the American Psychiatric Association.

Related Links:

— “VA Study Shows Patients With Schizophrenia Least Likely to Discontinue Clozapine, LAI Antipsychotics, Psychiatric News, July 19, 2021

Healio (7/19, Gramigna) reports, “Individuals with mental disorders, particularly those with schizophrenia, received less screening and lower-quality treatment for cardiovascular disease,” investigators concluded in a systematic review and meta-analysis that “included 47 studies with a total of 24,400,452 individuals, of whom 1,283,602 had mental disorders.” The findings were published online July 14 in the American Journal of Psychiatry, a publication of the American Psychiatric Association.

Related Links:

— “Individuals With Mental Disorders May Receive Less Screening, Lower-Quality Treatment For Cardiovascular Disease, Systematic Review Suggests “Joe Gramigna, Healio, July 19, 2021